Protagonist Therapeutics Inc Stock News

Invesco Ltd. increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 79.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,122 shares of the companys stock after buying an additional 8,019 shares during the quarter. Invesco Ltd.s holdings in Protagonist Therapeutics were worth $814,000 []

Protagonist Therapeutics Inc. (NASDAQ:PTGX) price on Friday, December 10, fall -1.76% below its previous days close as a downside momentum from buyers pushed the stocks value to $31.81. A look at the stocks price movement, the close in the last trading session was $32.38, moving within a range at $31.68 and $33.06. The beta value Protagonist Therapeutics Inc. (PTGX) Outlook: Looking Back For Insights Read More »

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has been given a consensus recommendation of Buy by the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12-month target price among brokers []

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases Drug And Focus On PN-235 P

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases Drug And Focus On PN-235 Protagonist Therapeutics (NASDAQ: PTGX ) said it has selected PN-235 as the final candidate for all clinical studies in multiple indications based on intervention of the Interleukin-23 pathway, under its collaboration with Johnson & Johnson, Inc.''s (NYSE: JNJ ) Janssen unit. In addition to the previously announced Phase 2 clinical study of PN-235 in psoriasis, new Phase 2 clinical studies of PN-235 in inflammatory bowel diseases are expected to commence in late 2022. Further development of PN-232 will be discontinued in favor of PN-235 based on its superior potency, and overall pharmacokinetic and pharmacodynamic profile, the company added. The stock was down 3.64% to $31.50 in premarket trading. Click here to access Benzinga''s FDA Calendar Bristol-Myers Squibb Says Application For Expanding Label For Reblozyl Accepted For Priority Review Bristol-Myers Squibb Company (NYSE: BMY ) announced that the U.S.

Protagonist Therapeutics Inc (NASDAQ: PTGX) has selected PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on the intervention of the Interleukin-2

NEWARK, Calif., Dec. 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Prudential Financial Inc. lessened its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 11.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,845 shares of the companys stock after selling 3,770 shares during the quarter. Prudential Financial Inc.s holdings []

UBS Asset Management Americas Inc. lifted its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 10.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,598 shares of the companys stock after acquiring an additional 2,598 shares during the period. []

Analysts expect Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to report earnings per share (EPS) of ($0.79) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Protagonist Therapeutics’ earnings. The lowest EPS estimate is ($0.97) and the highest is ($0.70). Protagonist Therapeutics reported earnings per share of ($0.48) in the same quarter […]

Wall Street analysts expect that Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will announce sales of $7.38 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Protagonist Therapeutics’ earnings. The lowest sales estimate is $7.00 million and the highest is $7.50 million. Protagonist Therapeutics posted sales of $5.65 million in […]

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) saw a large growth in short interest in October. As of October 29th, there was short interest totalling 4,430,000 shares, a growth of 18.4% from the October 14th total of 3,740,000 shares. Based on an average daily trading volume, of 1,890,000 shares, the days-to-cover ratio is presently 2.3 days. Currently, 10.5% []

Amalgamated Bank bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 7,807 shares of the companys stock, valued at approximately $350,000. Other institutional investors have also recently made changes to their positions in the []

AQR Capital Management LLC lowered its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 12.4% in the 2nd quarter, Holdings Channel.com reports. The fund owned 26,608 shares of the companys stock after selling 3,779 shares during the period. AQR Capital Management LLCs holdings in Protagonist Therapeutics were worth $1,194,000 at the end of the []